Portal de investigación
AML-457 Oral Azacitidine (Oral-AZA) in Patients With Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Ravandi F.
- Wei A.H.
- Döhner H.
- Sayar H.
- Dombret H.
- Selleslag D.
- Porkka K.
- Jang J.H.
- Skikne B.
- Beach C.L.
- Tian Y.O.
- Roboz G.J.
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 2152-2650, 2152-2669
- Tipo:
- Article
- Páginas:
- 252-253
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 0,778 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
Clinical Lymphoma Myeloma & Leukemia CIG MEDIA GROUP, LP
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Keywords
- azacitidine; placebo; acute myeloid leukemia; adult; Article; cancer chemotherapy; cancer risk; cancer survival; cancer survivor; controlled study; cytogenetics; ECOG Performance Status; follow up; human; intermediate risk patient; leukemia remission; major clinical study; minimal residual disease; overall survival; phase 3 clinical trial; randomized controlled trial; risk assessment
Campos de Estudio
Cita
Ravandi F,Wei AH,Döhner H,Sayar H,MONTESINOS P,Dombret H,Selleslag D,Porkka K,Jang JH,Skikne B,Beach CL,Tian YO,Roboz GJ. AML-457 Oral Azacitidine (Oral-AZA) in Patients With Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial. Clin. Lymphoma Myeloma Leukemia. 2022. 22. p. 252-253. IF:2,700. (3).